Watermark
  Back to Search Results

AdvanTIG-302

Active, not recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

AdvanTIG-302

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04746924

EudraCT Number Info icon SVG graphic used for tooltips or additional information.

2020-004985-21

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20211476/CTR20211464

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

No Study Documents

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

No Study Documents